Active Biotech is focusing on research and development of compounds in therapeutic areas of high medical need, in which the body's immune system is of central importance. The project portfolio comprises projects in development for neurodegenerative diseases, autoimmunity and cancer. Active Biotech operations are primarily focused on the ongoing partnerships within the laquinimod and ANYARA projects.
Active Biotech has an agreement with Teva Pharmaceutical Industries Ltd. for the worldwide development and commercialization of laquinimod. There are clinical trials ongoing with laquinimod in Relapsing remitting MS, Primary progressive MS and Huntington's disease.
Since October 2016, Active Biotech has an agreement with NeoTX, an immuno-oncology company, for the continued development of ANYARA.
For the tasquinimod, paquinimod and SILC projects, Active Biotech are seeking partners for the continued development.